Yahoo
Shanghai - Delayed Quote CNY

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196.SS)

22.66 +0.35 (+1.57%)
At close: October 30 at 3:00:01 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
42,731,256.72
41,661,612.75
41,067,195.86
41,399,539.59
43,951,546.90
Cost of Revenue
20,894,588.75
20,800,103.19
21,365,573.97
21,595,308.76
23,169,690.42
Gross Profit
21,836,667.97
20,861,509.56
19,701,621.89
19,804,230.83
20,781,856.48
Operating Expense
18,498,234.15
17,715,355.56
16,498,479.85
18,240,906.77
17,145,016.83
Operating Income
3,338,433.82
3,146,154
3,203,142.04
1,563,324.06
3,636,839.65
Net Non Operating Interest Income Expense
-977,105.54
-1,001,267.60
-1,097,160.93
-997,350.08
-709,762.38
Pretax Income
5,153,412.81
5,111,983.26
4,169,281.68
3,264,567.88
4,574,381.58
Tax Provision
714,458.85
864,053.64
656,841.29
369,504.45
626,917.46
Net Income Common Stockholders
3,514,759.23
3,370,561.56
2,769,886.63
2,386,265.81
3,730,804.58
Basic EPS
1.33
1.27
1.04
0.89
1.43
Diluted EPS
1.33
1.27
1.04
0.89
1.43
Basic Average Shares
2,642,721.94
2,653,985.48
2,663,352.53
2,681,197.54
2,608,954.25
Diluted Average Shares
2,642,721.94
2,653,985.48
2,663,352.53
2,681,197.54
2,608,954.25
Total Operating Income as Reported
5,250,609.03
5,228,351.34
4,245,103.91
3,307,507.91
4,656,656.38
Total Expenses
39,392,822.90
38,515,458.75
37,864,053.82
39,836,215.53
40,314,707.25
Net Income from Continuing & Discontinued Operation
3,514,759.23
3,370,561.56
2,769,886.63
2,386,265.81
3,730,804.58
Normalized Income
3,245,341.21
3,809,445.63
2,729,556.13
3,072,203.21
6,069,937.75
Interest Income
258,689.89
300,503.66
373,210.31
363,645.39
282,634.64
Interest Expense
1,212,983.03
1,265,350.72
1,431,914.68
1,324,830.53
963,806.92
Net Interest Income
-977,105.54
-1,001,267.60
-1,097,160.93
-997,350.08
-709,762.38
EBIT
6,366,395.84
6,377,333.98
5,601,196.36
4,589,398.40
5,538,188.50
EBITDA
6,366,395.84
9,890,367.56
8,602,739.35
7,554,583.03
7,874,099.75
Reconciled Cost of Revenue
20,894,588.75
20,800,103.19
21,365,573.97
21,595,308.76
23,169,690.42
Reconciled Depreciation
3,153,607.27
3,513,033.57
3,001,542.99
2,965,184.63
2,335,911.25
Net Income from Continuing Operation Net Minority Interest
3,514,759.23
3,370,561.56
2,769,886.63
2,386,265.81
3,730,804.58
Total Unusual Items Excluding Goodwill
312,781.40
-528,155.64
47,872.47
-773,485.37
-2,710,623.17
Total Unusual Items
312,781.40
-528,155.64
47,872.47
-773,485.37
-2,710,623.17
Normalized EBITDA
6,053,614.44
10,418,523.20
8,554,866.88
8,328,068.40
10,584,722.91
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
43,363.39
-89,271.58
7,541.97
-87,547.97
-371,490
12/31/2022 - 8/7/1998

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: